Venezuela Medical Device Regulation: Registration Fees and Budget Planning
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
A cost budget for medical device registration in Venezuela has to carry three lines simultaneously: official fees, service fees, and exchange rate and payment losses. The GRZAN practical estimate range is approximately VES 50,000–300,000 for official fees and approximately US$12,000–35,000 for service fees.
The conclusion is that what actually drives a budget out of control is not the official fee but the third line. In an environment of continuous currency depreciation and unpredictable foreign exchange approval, exchange losses and the cost of funds tied up during approval can exceed the official fees themselves. Projects that model only the first two lines tend to look affordable at the approval stage and expensive by the time the certificate is issued.
The third line is also the one that no quotation captures. Service providers quote in dollars, the authority charges in bolivars, the bank charges for conversion, and the payment channel adds its own compliance overhead. Each of those steps has a cost, and the sum of them is a real cost of the project even though no single invoice shows it.
2. Legal basis
| Instrument | Reference | Publication date | Provision / key point |
|---|---|---|---|
| Decreto N° 4.944 (customs tariff) | G.O. N° 6.804 Extraordinario | 25 April 2024 | Tariff framework, the reference basis for fee calculation |
| Circular N° DGSACS/0002/2025 | DGSACS/0002/2025 | 28 October 2025 | Payments move to the COMEX platform together with the procedure |
| Código Orgánico Tributario | Currently in force | — | Fines denominated in tax units (UT) |
| Venezuela Sanctions Regulations | 31 CFR Part 591 | Currently in force | Compliance constraints on the payment channel, where applicable |
Basis note: the ranges of VES 50,000–300,000 in official fees and US$12,000–35,000 in service fees are a GRZAN practical estimate, compiled from the firm’s project experience and industry ranges. They are not an officially published Venezuelan fee schedule. A tiered schedule denominated in Petro (class I at 1 Petro, class II at 1.5, class III at 1.75, class IV at 2) existed historically; that method of denomination no longer applies in current practice and is recorded here for background only. Project budgets must follow the fee schedule published by the receiving authority for the relevant period.
3. Expert insights
Insight 1: the basis for calculating official fees has changed fundamentally, and understanding that is the precondition for reading the current position. Venezuela once required registration fees to be denominated in the cryptocurrency Petro, with currency conversion performed through a virtual calculator on the day of payment. That mechanism no longer applies. Official fees are now denominated in bolivars and adjusted with the UT, so their dollar equivalent moves over time. A fee figure recorded a year ago is a historical record, not a planning input.
Insight 2: the tiered fee structure is linked to risk classification. The logic of tiered charging is that higher risk attracts a higher fee. Because two industry classification conventions coexist (article 08), the fee tier can differ depending on which classification convention is applied. The classification position should be settled before a fee tier is applied to a budget, otherwise the number will be internally consistent but externally wrong.
Insight 3: service fees are the largest controllable line in the budget. Service fees cover the local representative, document authentication and translation, dossier preparation, platform operation, follow-up and deficiency responses. Authentication and translation costs scale with the number of products, while representative fees are mostly a fixed annual amount. Multi-product projects can therefore dilute unit cost substantially through consolidated filing (article 15). The choice of product sequencing is thus a cost decision as much as a regulatory one: filing the most commercially important product first, with the rest grouped, usually produces a lower average cost per registration than filing each product separately as orders arrive.
Insight 4: the third line, exchange rate and payment losses, is the easiest to overlook. It has three parts: the change in the dollar equivalent of official fees caused by currency depreciation, the cost of funds tied up while foreign exchange approval is pending, and the transaction fees and compliance costs of the cross-border payment channel. Under sanctions, the choice of payment channel can generate additional compliance costs (article 40). None of these items appears on a quotation, and all of them appear in the final accounts.
Insight 5: budgeting should be revisited at fixed intervals, not once. Because each of the three lines moves for its own reason, a budget approved at project initiation has a limited useful life. A quarterly review, with the official fee line recalculated at the current UT and the exchange line updated to the prevailing rate, keeps the sponsor’s expectations aligned with reality and avoids the situation in which additional funding has to be requested at the point of payment.
4. Practical recommendations
- Present the budget as three separate lines (official fees, service fees, exchange and payment losses), with the third reserved at 10%–20% of the sum of the first two (practical estimate).
- Prepare the official fee line anchored to the UT or to US dollars, and recalculate the bolivar amount immediately before payment.
- For multi-product projects, assess consolidated filing first in order to dilute authentication, translation and representation costs.
- Agree the currency of denomination and the adjustment mechanism for fees in the agreement with the authorized representative, so that currency movements do not become a dispute.
- For projects involving dollar settlement, confirm the payment channel in advance and estimate the channel cost as a separate budget item.
5. Verification checklist
- □ Budget presented as three separate lines (official fees, service fees, exchange and payment losses)
- □ Current official fee schedule verified with the receiving authority rather than carried forward from historical data
- □ The product’s risk classification tier and the corresponding fee tier have been confirmed
- □ Multi-product projects have been assessed for the cost dilution available through consolidated filing
- □ The representation agreement specifies the currency of denomination and the adjustment mechanism
Regulatory information verified as of October 29, 2026.
GRZAN supports medical device manufacturers, importers and authorized representatives with registration work in Venezuela, including three-line cost budgeting, fee schedule verification and consolidated filing strategy. Whether you need a project budget or hands-on filing support, our regulatory team can help. Contact us at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us